The depletion of CD8+ T cells significantly impeded the remarkable antitumor efficacy of Tri-NAb, as evidenced by the tumor growth curves; similarly, the depletion of NK cells had a substantial impact on the antitumor effect of Tri-NAb, particularly on the complete remission rate (CR). Here, CD8A is linked to neoplasm.